ZEMDRI (PLAZOMICIN): payments to doctors
Payments that named ZEMDRI (PLAZOMICIN) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $144K
- Providers
- 205
- Transactions
- 491
- Average per transaction
- $293
The per-transaction average — $293 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 205 providers the average total is $703, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Cipla USA Inc. | $144,063 | 100.0% |